Business Wire

Laserfiche Recognized as a 2025 Gartner® Peer Insights™ “Customers’ Choice” for Document Management

8.7.2025 16:00:00 CEST | Business Wire | Press Release

Share

Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has been named a Customers’ Choice in the 2025 Gartner Peer Insights ‘Voice of the Customer’: Document Management report. This distinction is based on customer reviews. Vendors placed in the upper-right “Customers’ Choice” quadrant of the “Voice of the Customer” have scores that meet or exceed the market average for both axes (User Interest and Adoption, and Overall Experience).

“We’re proud to be the only company recognized both as a Leader in the latest Magic QuadrantTM for Document Management and in the upper-right quadrant of the ‘Voice of the Customer’ report,” said Thomas Phelps IV, SVP of Corporate Strategy and Chief Information Officer at Laserfiche. “We believe both of these recognitions highlight our unwavering commitment to customer-centric innovation and delivering on our core value: ‘Drive Change, Deliver Results.’”

In the Gartner report, Laserfiche received a 4.7-star rating based on 308 reviews as of March 31, 2025. Laserfiche had a 92% Willingness to Recommend from reviewers.

Gartner Peer Insights is a public platform that offers verified, first-hand reviews of enterprise technology solutions by end-user professionals for end-user professionals.

According to Gartner, “Gartner estimates that 70% to 80% of enterprise information is unstructured, posing a significant challenge for organizations that must unlock the potential and mitigate the risks of content. Document Management tools are critical to enterprise application strategies that need to support unstructured information or content.”

“Laserfiche is a best-in-class product that has been instrumental in our growth and innovation," said David Hixson, CIO at West-Mark. “Laserfiche's data governance and automation tools have allowed us to cut processing times, optimize supply chain purchasing and avoid added costs for oversupplying components. As West-Mark expands, this level of efficiency will allow staff to stay focused on delivering high quality products and customer service.”

Our highlights of Gartner® Peer Insights™ reviews include:

  • "Laserfiche is enabling us to create an enterprise approach to our records management, allowing my agency to use records in an efficient and actionable way. Laserfiche offers support around the clock, giving us the security we need and less to no down time, which is critical to my agency." — Chief Data Officer in Government
  • "Working with Laserfiche has truly been one of the better experiences. Our end users love the tool and every department at the school wants to use Laserfiche to automate their processes. To date the college has achieved savings by eliminating inefficiencies that accompany any manual process. Laserfiche has been a great fit for our organization." — Managing Director, Records & Information in Education
  • "We have been using Laserfiche for about two years and continue to be impressed by the robustness of the software and the continued development of additional features and components. Very powerful workflow is probably the highlight of the suite of software, but the Quick Fields scanning is the most impressive scanning software I've ever personally used." — Business Intelligence Director in Consumer Goods Industry

Organizations optimize workflows, accelerate human productivity and strengthen information governance with Laserfiche. In June 2025, the company launched AI innovations to boost productivity and enable automation at scale. Smart Fields, an out-of-the-box intelligent capture tool, allows customers to extract data automatically using natural language instructions, no matter the source or format. Smart Chat provides an intuitive chat interface that enables users to quickly gain insights from your repository content using AI.

To learn more about how customers rated Laserfiche, download a complimentary copy of the 2025 Gartner Peer Insights ‘Voice of the Customer’: Document Management report here.

About Gartner Peer Insights

Gartner Peer Insights is a public platform that offers verified, first-hand reviews and ratings of enterprise technology solutions by end-user professionals for end-user professionals.

The “Voice of the Customer” is a document that applies a methodology to aggregated Gartner Peer Insights’ reviews in a market to provide an overall perspective for IT decision makers. For more information, please visit www.gartner.com/reviews/home.

Gartner Disclaimers

Gartner, Voice of the Customer for Document Management, Peer Contributors, 26 June 2025.

GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.

Gartner® and Peer Insights™ are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved. Gartner® Peer InsightsTM content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

About Laserfiche

Laserfiche is a leading enterprise platform that helps organizations digitally transform operations and manage their content with AI-powered solutions. Through scalable workflows, customizable forms, no-code templates and AI-enabled capabilities, the Laserfiche® document management platform accelerates how business gets done. Trusted by organizations of all sizes — from startups to Fortune 500 enterprises — Laserfiche empowers teams to boost productivity, foster collaboration, and deliver a superior customer experience at scale. Headquartered in Long Beach, California, Laserfiche operates globally, with offices across North America, Europe, and Asia.

Connect with Laserfiche:

Laserfiche Blog | X | LinkedIn | Facebook | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20250708562166/en/

Contacts

Media contact:
Linda Domingo
Communications Director, Laserfiche
Linda.domingo@laserfiche.com | 562-988-1688 x 234

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye